EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression

Takashi Yokoyama iD, Masao Saitoh, Keiji Miyazawa iD

Cancer Science · 2025

DOI: 10.1111/cas.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Takashi Yokoyama und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Graduate School of Medicine, University of Yamanashi, Chuo, Japan. Hauptthemen laut MEDLINE: Doxorubicin, Drug Resistance, Neoplasm, Transforming Growth Factor beta, Aldehyde Dehydrogenase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transforming growth factor‐β (TGF‐β)/Smad signaling pathway promotes malignant transformation through various mechanisms, and its effect on enhancing drug resistance can limit the efficacy of treatment. Here, we showed that pre‐stimulation of human lung cancer A549 cells with TGF‐β increases resistance to doxorubicin‐induced growth inhibition in a Smad3‐ and Smad4‐dependent manner. This effect was suppressed by the aldehyde dehydrogenase (ALDH) inhibitor oxyfedrine, suggesting that ALDH family members are involved in drug resistance. TGF‐β upregulated the mRNA and protein expression of ALDH1A1. The TGF‐β/Smad3 transcriptional enhancer region on ALDH1A1 was identified by Smad3 ChIP‐seq analysis using an open database and by reporter assays. Knockdown of ALDH1A1 in A549 cells suppressed TGF‐β–induced doxorubicin resistance, and lentivirus‐mediated introduction of ALDH1A1 into A549 SMAD3 ‐KO cells restored drug resistance. We also demonstrated that ALDH1A1 is required and sufficient for TGF‐β/Smad3 signaling–induced anchorage‐independent growth. The results suggest that the TGF‐β/Smad3/4 axis promotes resistance to doxorubicin and anchorage‐independent growth by inducing the transcription of ALDH1A1 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinDrug Resistance, NeoplasmTransforming Growth Factor betaAldehyde DehydrogenaseLung NeoplasmsHumansAldehyde Dehydrogenase 1 FamilyRetinal DehydrogenaseSignal TransductionA549 CellsSmad3 ProteinGene Expression Regulation, NeoplasticCell ProliferationCell Line, TumorSmad4 Protein

Stichwörter der Autor:innen

ALDH1A1SmadTGF‐βdoxorubicindrug resistance

Substanzen

DoxorubicinAldehyde Dehydrogenase 1 FamilyTransforming Growth Factor betaRetinal DehydrogenaseALDH1A1 protein, humanSmad3 ProteinAldehyde DehydrogenaseSMAD3 protein, humanSmad4 ProteinSMAD4 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry, Graduate School of Medicine, University of Yamanashi, Chuo, Japan.
  • Center for Medical Education and Sciences, Graduate School of Medicine, University of Yamanashi, Chuo, Japan.

ORCID-Profile: Takashi Yokoyama, Keiji Miyazawa

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Yokoyama, T., Saitoh, M., & Miyazawa, K. (2025). TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression. Cancer Science. https://doi.org/10.1111/cas.70109

Vancouver

Yokoyama T, Saitoh M, Miyazawa K. TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression. Cancer Science. 2025. doi:10.1111/cas.70109

BibTeX
@article{Yokoyama2025,
  author = {Yokoyama, Takashi and Saitoh, Masao and Miyazawa, Keiji},
  title = {TGF ‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70109}
}
Kostenlos starten →